|Bid||195.86 x 800|
|Ask||195.92 x 200|
|Day's Range||195.24 - 197.59|
|52 Week Range||163.31 - 210.19|
|Beta (3Y Monthly)||1.39|
|PE Ratio (TTM)||61.01|
|Earnings Date||Jan 30, 2019 - Feb 4, 2019|
|Forward Dividend & Yield||5.80 (3.03%)|
|1y Target Est||204.80|
Of the 26 analysts covering Regeneron Pharmaceuticals (REGN), eight recommend “buy” or a higher rating, 17 recommend “hold,” and one recommends “sell.” Their mean rating for Regeneron stock is 2.58, and their target price is $426.05, implying a 12.8% upside for the stock based on its December 10 closing price of $377.59.
In this year’s third quarter, Regeneron Pharmaceuticals’ (REGN) interest expenses rose YoY (year-over-year) to $7.49 million from $6.18 million, and its net other income rose YoY to $16.43 million from $11.86 million. Its income tax expenses fell YoY to $41.21 million from $177.29 million.
THOUSAND OAKS, Calif., Dec. 11, 2018 /PRNewswire/ -- Amgen (AMGN) today announced a novel multi-year collaboration with Magellan Rx Management, the pharmacy benefit management division of Magellan Health, that will leverage each company's capabilities and resources to identify clinical gaps for some of the healthcare system's most difficult-to-treat diseases. Based on Amgen and Magellan's extensive expertise in complex areas of health and specialty populations, the initial projects will focus on improving patient outcomes for the treatment of osteoporosis and migraine.
How's Seattle Genetics Positioned? For fiscal 2018 and 2019, Seattle Genetics’ gross margins are expected at 88.54% and 88.58%, respectively, as compared with gross margins of 88.78% for fiscal 2017. In comparison, the fiscal 2018 gross margins of peers Amgen (AMGN), Gilead Sciences (GILD), and Eli Lilly & Co (LLY) are expected at 85.83%, 84.81%, and 76.05%, respectively.
Seattle Genetics (SGEN) had generated net investment and other income of $82.22 million in the third quarter of 2017. In the third quarter of 2018, on the other hand, it incurred net investment and other loss of $21.87 million.
How's Seattle Genetics Positioned? Seattle Genetics (SGEN) is a biotechnology company with a focus on developing and bringing to market targeted therapies for cancer. Seattle Genetics generated total revenues of $169.42 million in the third quarter of 2018 as compared with $135.29 million in the comparable period of 2017.
Hopping in and out of stocks tends to do more harm than good to your portfolio. Fortunately, most of the time, investors are content to sit back and let time do the heavy lifting. Every now and then, however, an uninterrupted market-wide rally (such as the one we saw in 2017) followed by a couple of major corrections (such as the ones we've seen in 2018) inspires a more active approach. Buying every dip last year was a bulletproof strategy; steering clear of this year's big dips would've left most investors far better off. But broadly speaking, investors shouldn't embrace that short-term mindset. Buy-and-hold is a time-tested strategy that helps investors avoid trying to time the market (which even experts can't reliably do) and making poor emotional decisions. With that as a backdrop, here are a dozen stocks to never sell. Many buy-and-holders are looking to reset their portfolios as the new year begins. If you hold any of the stocks, don't stop ... and if you're looking to buy, be ready to commit. Each company has plenty to success that their history of success should continue for years to come. And each operates in an industry that won't go away anytime soon. SEE ALSO: 101 Best Dividend Stocks to Buy for 2019 and Beyond
In the third quarter of this year, Regeneron Pharmaceuticals’ (REGN) selling, general, and administrative expenses rose YoY (year-over-year) to $369.23 million from $306.77 million, primarily due to a higher employee headcount. Meanwhile, its R&D (research and development) expenses rose YoY to $556.97 million from $529.75 million. It had R&D expenses of $2.03 billion and $2.23 billion, respectively, in fiscal 2018 and fiscal 2019, compared with $2.07 billion in fiscal 2017.
In fiscal 2018 and fiscal 2019, Regeneron Pharmaceuticals (REGN) is expected to generate revenue of $6.49 billion and $7.16 billion, respectively, compared with revenue of $5.87 billion in fiscal 2017. Meanwhile, peers Amgen (AMGN), Biogen (BIIB), and Johnson & Johnson (JNJ) are expected to have revenue of $23.36 billion, $13.31 billion, and $81.35 billion, respectively, in fiscal 2018. Regeneron’s cash per share is $20.14, while Amgen’s, Biogen’s, and Johnson & Johnson’s cash per share is $45.17, $21.31, and $7.20, respectively.
Shares of Entera Bio Ltd. and Amgen Inc. rose Tuesday, after they announced a research collaboration in inflammatory disease and other serious illnesses. As part of the deal, Entera will use its proprietary drug delivery platform to develop oral versions of one preclinical large molecule program selected by Amgen. Amgen has the option of selecting two other programs to add to the collaboration. Entera will be eligible to receive up to $270 million in aggregate payments, along with tiered royalties up to mid-single digits upon reaching various milestones. It will retain IP rights to its technology. Entera shares rose 11.5% in early trade and are up 23% in the last three months, while the S&P 500 has fallen 7.7%. Amgen shares were up about 1%.
THOUSAND OAKS, Calif. and SAN FRANCISCO, Dec. 10, 2018 /PRNewswire/ -- Amgen (AMGN) and the Lazarex Cancer Foundation, a non-profit organization focused on improving patient access to cancer clinical trials, today announced that they have teamed up to support more equitable access to clinical trials for cancer patients in the U.S. Through a corporate donation, Amgen has contributed $2 million to Lazarex's IMPACT (IMproving Patient Access to Cancer Clinical Trials) program, which is focused on improving patient enrollment, retention, minority participation and equitable access in oncology trials. IMPACT aspires to create a new standard in clinical trial outreach allowing all cancer patients, regardless of their ability to pay for travel and other expenses, to participate in clinical trials evaluating new cancer treatment options.
Amgen Inc. (AMGN) has informed the market Friday after closing bell that the board of directors of the company has authorized the payment of a quarterly dividend for the first trimester of fiscal 2019. The company will pay shareholders a cash dividend of $1.45 per share, reflecting a 9.8% increase from the previous one. Warning! GuruFocus has detected 2 Warning Signs with AABA.
Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 5.7% in the 12 months ending October 26 […]
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]
Amgen Inc. said late Friday its board of directors has declared a dividend of $1.45 a share for the first quarter of 2019. The dividend is payable March 8 to shareholders of record on Feb. 15. That represents a 10% increase from what Amgen paid in each of the previous four quarters. Shares of Amgen rose 0.2% in the extended session Friday after ending the regular trading day down 3.8%.
THOUSAND OAKS, Calif., Dec. 7, 2018 /PRNewswire/ -- Amgen (AMGN) today announced that its Board of Directors declared a $1.45 per share dividend for the first quarter of 2019. Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives.
Critics of high drug prices are launching a new line of attack against manufacturers of the medicines, faulting the firms for using savings from the tax overhaul to buy back shares rather than lower prices. The attacks began in October, when more than a dozen Democrats in the House of Representatives sent letters to five big pharmaceutical companies saying they had benefited from recent tax cuts but kept charging high prices. The letters singled out certain drugs whose list prices had increased and asked their manufacturers for details about price changes and the costs of research and advertising.
Will the yield curve invert, with short-term interest rates pushing their way above long-term interest rates … a relatively rare scenario that’s all too often associated with a troubled economy? A true inverted yield curve has not happened yet, but as of right now we’re as close to an inverted yield curve as we’ve been in a decade. Translation: It sure couldn’t hurt to go ahead and make plans for an inverted yield curve, just in case that’s how things take shape.